As of Feb 03, 2025, IDEXX Laboratories, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $133.5. This suggests it may be overvalued by (71.5%) compared to its current price of around $469.0, using a WACC of 10.7% and growth rates of 3.0%.
As of Feb 03, 2025, IDEXX Laboratories, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 10.7%.
As of Feb 03, 2025, IDEXX Laboratories, Inc.'s Enterprise Value (EV) is approximately $11.6B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.